Grrrrrr. On Monday morning, Atrix Laboratories
As I wrote back in April, Atrix has been flawless in executing its business plan. Its lead drug for the treatment of prostate cancer, Eligard, was making inroads against entrenched competition from Abbott's
Given that Atrix is profitable and has a deep pipeline of interesting drug programs, I am not at all surprised that another company was interested in making the acquisition. To take QLT's point of view for a second, it seems to be a pretty good move as it fills out the firm's thin pipeline and reduces its dependence upon Visudyne, which could soon be facing competition from Genentech's
During the conference call, Atrix's management said it didn't have the resources to rapidly advance drug candidates without returning back to unprofitability. That's an argument I can buy. The combined QLT/Atrix entity will definitely be able to spend more on R&D than Atrix could have by itself.
At the same time, I wonder if Atrix shareholders would have been better off if management had held off for another year; 2005 was poised to be a good year for Atrix with the possible approvals of the new Eligard formulation and its next drug, Atrisone, to treat acne. With additional approved drugs in hand, a better offer than $35 per share could possibly have been had.
To read more by Charly on the exciting biotech industry, check out his recent articles:
Fool contributor Charly Travers owns shares of Atrix Laboratories.